shigellosi
acut
invas
diseas
lower
intestin
afflict
million
peopl
worldwid
estim
one
million
fatal
per
annum
despit
extens
research
last
two
decad
vaccin
multidrug
resist
shigella
yet
avail
market
provid
safe
effect
broadspectrum
vaccin
shigella
explor
food
grade
bacteria
lactococcu
lacti
l
lacti
deliveri
conserv
antigen
protein
outer
membran
protein
ompa
mucos
site
effect
elicit
system
mucos
immun
previous
confirm
immunogen
potenti
recombin
l
lacti
express
ompa
lacvax
ompa
balbc
mice
present
studi
character
humor
cellular
immun
profil
lacvax
ompa
assess
protect
efficaci
use
newli
develop
human
like
murin
shigellosi
model
signific
increas
ompa
specif
serum
igg
fecal
siga
domin
immun
respons
indic
high
ratio
lacvax
ompa
immun
mice
reveal
success
activ
humor
cellular
immun
lacvax
ompa
immun
anim
also
protect
humanlik
shigellosi
challeng
flexneri
atcc
antigen
specif
serum
igg
fecal
siga
infc
level
found
signific
correl
protect
collect
result
suggest
lacvax
ompa
promis
prophylact
candid
shigellosi
howev
protect
efficaci
lacvax
ompa
higher
anim
would
strengthen
futur
applic
human
shigella
gram
neg
bacteria
import
etiolog
agent
respons
acut
invas
bloodi
dysenteria
commonli
known
shigellosi
bacillari
dysenteria
respons
childhood
morbid
mortal
remain
major
public
health
problem
recurr
shigella
infect
children
also
result
poor
absorpt
nutrient
intestin
lead
stunt
growth
impair
cognit
develop
variou
longterm
health
problem
diseas
burden
maximum
resourcepoor
set
mani
million
diarrheal
episod
report
everi
year
around
death
occur
due
shigellosi
case
report
amongst
militari
personnel
travel
industri
countri
major
factor
respons
high
incid
shigellosi
develop
countri
lack
clean
water
poor
sanit
malnutrit
public
health
strategi
reduc
exposur
transmiss
effect
establish
mani
develop
countri
especi
context
conflict
mass
displac
suscept
person
remain
challeng
control
shigella
infect
antibiot
along
oral
rehydr
therapi
gener
use
howev
last
decad
shigella
strain
resist
ampicillin
chloramphenicol
nalidix
acid
tetracyclin
trimethoprim
sulfamethoxazol
ciprofloxacin
isol
increas
frequenc
asia
africa
rapid
emerg
multidrug
resist
shigella
spp
increas
number
infect
person
develop
countri
pose
urgent
need
develop
effect
prophylact
shigella
despit
numer
effort
http
elsevi
ltd
right
reserv
past
decad
present
licens
vaccin
avail
market
sever
candid
vaccin
current
differ
preclin
clinic
stage
shigella
spread
contamin
food
water
reach
colon
wherein
enter
intestin
epithelium
preferenti
via
cell
intern
bacteria
spread
intracellularli
result
inflamm
follow
cell
death
dysenteria
henc
desir
vaccin
candid
elicit
effici
system
well
mucos
immun
respons
regard
group
explor
food
grade
lactococcu
lacti
antigen
dna
vaccin
deliveri
vehicl
enter
pathogen
shigella
develop
noninvas
invas
rl
lacti
harbour
dna
vaccin
report
plasmid
evalu
dna
deliveri
potenti
strain
vitro
well
vivo
oral
immun
rl
lacti
harbour
dna
vaccin
report
plasmid
pperdbi
lacvax
dnai
result
system
mucos
immun
respons
model
antigen
egfp
use
food
grade
l
lacti
antigen
dnaprotein
deliveri
vehicl
offer
sever
advantag
attenu
pathogen
immunostimulatori
properti
capabl
surviv
transit
stomach
gra
gener
regard
safe
statu
pave
way
applic
mucos
deliveri
numer
antigen
therapeut
candid
l
lacti
live
vaccin
vector
exploit
deliveri
listeriolysin
llo
protein
listeria
monocytogen
sarscoronaviru
nucleocapsid
protein
tetanu
toxin
fragment
c
ttfc
antigen
helicobact
pylori
hein
et
al
exploit
l
lacti
develop
nonliv
bacteriumlik
particl
blp
display
ipab
ipad
show
induct
protect
immun
differ
strain
shigella
adult
infant
mice
use
live
l
lacti
group
also
demonstr
first
time
immunogen
potenti
live
rl
lacti
express
outer
membran
protein
ompa
shigella
dysenteria
balbc
mice
oral
immun
rl
lacti
psec
ompa
lacvax
ompa
result
better
system
mucos
immun
respons
ompa
intranas
rout
immun
present
studi
character
immun
respons
follow
oral
immun
lacvax
ompa
defin
correl
protect
moreov
use
newli
develop
inhous
shigellosi
murin
model
evalu
protect
efficaci
lacvax
ompa
best
knowledg
first
report
describ
potenti
applic
live
l
lacti
base
vaccin
deliveri
platform
provid
protect
immun
respons
flexneri
bacteri
strain
plasmid
use
present
studi
list
tabl
briefli
flexneri
atcc
grown
nutrient
broth
himedia
laboratori
india
rpm
h
lactococcu
lacti
rl
lacti
psec
ompa
lacvax
ompa
strain
grown
static
broth
difco
laboratori
franklin
lake
nj
usa
supplement
wv
steril
glucos
chloramphenicol
ad
mgml
concentr
lacvax
ompa
around
pathogen
free
femal
balbc
mice
weigh
g
procur
mahaveera
enterpris
hyderabad
india
hous
b
v
patel
perd
centr
anim
hous
accord
committe
purpos
control
supervis
experi
anim
cpcsea
guidelin
group
three
mice
hous
polypropylen
cage
steril
bed
control
light
light
dark
temperatur
rel
humid
mice
given
free
access
food
steril
water
steril
water
bottl
bed
materi
replac
everi
day
anim
experi
done
accord
institut
anim
ethic
committe
schemat
represent
studi
design
depict
fig
briefli
anim
divid
three
group
group
twelv
mice
oral
immun
either
cfu
control
strain
l
lacti
ow
recombin
vaccin
strain
lacvax
ompa
phosphat
buffer
salin
pb
os
bacteri
strain
grown
mention
section
induc
ngml
nisin
h
cell
harvest
centrifug
min
resuspend
ml
pb
obtain
cfu
blood
sampl
collect
day
fecal
sampl
collect
day
tabl
day
group
randomli
subdivid
two
subgroup
n
group
one
subgroup
challeng
flexneri
atcc
group
sacrif
splenocyt
isol
pathophysiolog
paramet
ompa
specif
serum
igg
fecal
iga
antibodi
detect
enzym
link
immunosorb
assay
elisa
describ
yagnik
et
al
elisa
result
express
optic
densiti
od
valu
measur
nm
multiskan
go
micropl
spectrophotomet
thermo
scientif
usa
dilut
serum
fecal
extract
six
mice
immun
subgroup
sacrif
day
last
booster
spleen
remov
spleno
cyte
isol
previous
describ
pore
et
al
briefli
singl
cell
suspens
prepar
hank
balanc
salt
solut
medium
isol
spleen
use
lm
nylon
cell
strainer
bd
bioscienc
follow
erythrocyt
lysi
cell
resuspend
rpmi
medium
contain
fetal
bovin
serum
fb
concentr
cell
per
ml
cultur
well
plate
cell
incub
co
h
cell
restimul
purifi
ompa
h
supernat
collect
analys
quantif
infc
use
mous
elisa
readysetgo
kit
ebiosci
accord
manufactur
protocol
order
assess
protect
efficaci
lacvax
ompa
six
mice
immun
subgroup
challeng
intraperiton
cfu
flexneri
atcc
describ
previous
sharma
et
al
mice
observ
gener
physic
activ
pathophysiolog
paramet
bodi
weight
fur
ruffl
abdomin
swell
conjunct
consist
stool
pass
presenc
mucu
blood
fece
day
post
challeng
anim
euthan
day
vital
organ
small
intestin
larg
intestin
spleen
collect
colon
length
challeng
mice
measur
collect
tissu
subject
haematoxylin
eosin
h
e
stain
histopatholog
score
stain
intestin
section
blindli
score
rang
normal
sever
pathophysiolog
paramet
cell
death
crypt
lamina
propria
epithelium
muscl
layer
epithelium
exfoli
consid
assess
integr
whole
tissu
establish
shigella
infect
result
destruct
host
mucos
epithelium
lead
diarrheal
condit
base
cumul
histopatholog
score
rang
compris
individu
score
cell
death
crypt
lamina
propria
epithelium
muscl
layer
epithelium
exfoli
intestin
tissu
select
quantifi
paramet
defin
degre
infect
invers
relat
degre
protect
sinc
endpoint
present
studi
onset
diarrhoea
integr
intestin
tissu
architectur
use
defin
degre
protect
efficaci
vaccin
candid
follow
paramet
evalu
defin
correl
infectionprotect
serum
igg
fecal
siga
infc
statist
analys
perform
use
graphpad
prism
trial
version
oneway
anova
posthoc
bonferroni
multipl
comparison
test
use
determin
statist
signific
cytokin
level
colon
length
histopatholog
score
among
differ
experiment
anim
twoway
anova
posthoc
bonferroni
multipl
comparison
test
use
determin
statist
signific
serum
igg
fecal
siga
among
differ
experiment
anim
differ
time
point
linear
regress
follow
spearman
correl
confid
interv
ci
perform
evalu
correl
protect
previous
report
immunogen
potenti
oral
nasal
administ
rl
lacti
express
ompa
lacvax
ompa
dysenteria
balbc
mice
antibodi
titer
oral
vaccin
anim
previou
studi
wherea
present
studi
could
achiev
antiompa
titer
increas
vaccin
dose
fold
shown
fig
lacvax
ompa
immun
mice
group
show
signific
increas
antiompa
antibodi
progress
vaccin
regimen
p
product
antigen
specif
antibodi
evid
immedi
dose
lacvax
ompa
ie
day
reach
maximum
titer
day
last
booster
day
howev
mice
immun
wt
l
lacti
ow
salin
os
exhibit
signific
increas
antigen
specif
antibodi
titer
day
ompa
specif
igg
level
group
significantli
higher
antiompa
igg
titer
ow
p
os
p
group
fig
increas
serum
antiompa
igg
demonstr
immunogen
potenti
develop
vaccin
candid
lacvax
ompa
order
evalu
whether
lacvax
ompa
induc
mucos
immun
level
siga
hallmark
mucos
immun
measur
fecal
sampl
immun
anim
day
siga
level
significantli
higher
group
compar
ow
os
group
mice
p
interestingli
rise
siga
level
evid
even
day
post
last
booster
dose
p
indic
strength
l
lacti
base
antigen
deliveri
platform
elicit
mucos
immun
respons
antigen
specif
siga
antibodi
present
fecal
sampl
ow
os
group
well
day
fig
order
assess
cellular
immun
respons
cytokin
estim
supernat
restimul
splenocyt
vaccin
anim
shown
fig
vaccin
lacvax
ompa
result
significantli
higher
product
infc
p
princip
cytokin
p
p
compar
ow
os
group
investig
type
domin
cell
respons
ratio
repres
infc
cytokin
calcul
depict
fig
lacvax
ompa
immun
anim
show
significantli
high
ratio
suggest
indic
immun
respons
compar
control
anim
p
order
assess
protect
efficaci
vaccin
candid
previous
develop
human
like
shigellosi
murin
model
establish
diseas
paramet
observ
follow
intraperiton
shigella
infect
induct
diarrhoea
balbc
mice
one
salient
featur
mimic
human
shigellosi
present
studi
observ
sign
diarrhoea
lacvax
ompa
immun
mice
follow
challeng
flexneri
atcc
fig
contrast
os
ow
group
exhibit
diarrhoea
similar
human
shigellosi
fig
interestingli
also
observ
signific
differ
diarrheal
symptom
ow
os
group
wildtyp
l
lacti
receiv
ow
group
exhibit
semisolid
diarrheal
episod
contrast
salin
receiv
os
group
exhibit
frequent
liquid
diarrhoea
fig
observ
indic
protect
properti
food
grade
organ
l
lacti
maintain
integr
intestin
tissu
shigella
infect
earlier
report
develop
conjunct
consequ
system
spread
shigella
infect
balbc
mice
present
studi
observ
conjunct
salin
receiv
balbc
mice
os
follow
shigella
infect
case
ow
group
observ
support
protect
efficaci
vaccin
candid
lacvax
ompa
also
strengthen
protect
natur
vaccin
carrier
l
lacti
limit
shigella
penetr
spread
reduct
colon
length
one
key
indic
inflamm
tissu
destruct
present
studi
measur
colon
length
vaccin
anim
shigella
challeng
h
postshigella
challeng
day
post
shigella
challeng
note
colon
length
control
anim
ow
p
os
p
significantli
reduc
post
shigella
infect
interestingli
chang
colon
length
lacvax
ompa
immun
mice
day
shigella
infect
colon
length
challeng
anim
restor
normal
averag
length
indic
clearanc
shigella
infect
associ
inflamm
induct
mucos
system
immun
prevent
shigella
penetr
infect
therebi
inhibit
intestin
tissu
destruct
twenti
four
hour
post
shigella
challeng
tissu
integr
lacvax
ompa
immun
anim
exhibit
promin
chang
evid
cumul
histopatholog
score
assign
sampleblind
pathologist
wherea
control
group
anim
show
sever
tissu
destruct
mark
cell
death
crypt
p
lamina
propria
p
epithelium
p
muscl
layer
p
disturb
whole
tissu
integr
p
fig
shown
fig
antigen
specif
serum
igg
p
fecal
siga
p
infc
p
p
level
significantli
neg
correl
degre
infect
higher
level
antigen
specif
igg
siga
antibodi
cytokin
level
infc
group
anim
suggest
immunolog
paramet
protect
anim
shigella
infect
strong
correl
protect
nt
observ
signific
correl
degre
infect
immunolog
paramet
p
p
level
supplementari
fig
despit
numer
attempt
vaccin
develop
even
singl
licens
vaccin
avail
market
multidrug
resist
shigella
consid
potenti
threat
shigellosi
world
health
organ
place
develop
shigella
vaccin
top
prioriti
list
await
vaccin
enter
infect
variou
approach
use
develop
vaccin
shigella
includ
use
genet
attenu
shigella
kill
whole
cell
vaccin
subcellular
vaccin
opolysaccharideprotein
conjug
approach
either
suffer
low
immunogen
advers
side
effect
attenu
pathogen
vaccin
success
activ
arm
immun
provid
long
last
immun
pose
threat
revers
virul
phenotyp
side
purifi
antigen
compon
subunit
vaccin
safer
altern
attenu
pathogen
howev
fail
activ
cellular
immun
background
lactococcu
lacti
l
lacti
consid
attract
safe
altern
subunit
vaccin
attenu
pathogen
moreov
immunostimulatori
properti
l
lacti
act
adjuv
encourag
use
antigen
deliveri
vehicl
previous
report
rl
lacti
express
well
conserv
immunodomin
shigella
antigen
ompa
induc
antigen
specif
system
mucos
immun
respons
given
oral
balbc
mice
order
obtain
higher
antigen
specif
igg
siga
titer
increas
antigen
dose
assess
humor
respons
igg
antibodi
titer
increas
increas
vaccin
dose
serolog
igg
level
follow
oral
inocul
rl
lacti
express
ompa
significantli
higher
control
group
p
progress
increas
serum
igg
level
round
vaccin
administr
highest
serum
igg
titer
observ
day
post
last
booster
possibl
explan
could
increas
circul
antigen
specif
memori
b
cell
follow
last
booster
administr
observ
increas
antigen
specif
antibodi
titer
last
booster
dose
agreement
research
report
enhanc
antibodi
titer
last
vaccin
dose
nasal
administ
rl
lacti
express
pneumococc
protect
protein
pppa
present
work
protect
efficaci
develop
vaccin
candid
also
evalu
activ
human
like
shigellosi
murin
model
enter
invas
pathogen
shigella
breach
epitheli
barrier
establish
infect
presenc
commens
bacteria
antigen
specif
siga
resist
host
pathogen
interact
invas
pathogen
present
studi
immun
lacvax
ompa
result
four
fold
increas
ompa
specif
fecal
siga
siga
product
also
increas
day
post
vaccin
follow
similar
trend
serum
igg
presenc
siga
fecal
sampl
indic
stimul
mucos
immun
support
protect
efficaci
develop
vaccin
candid
order
evalu
activ
cellular
arm
immun
cytokin
profil
vaccin
anim
shigella
challeng
studi
indic
domin
respons
high
ratio
vaccin
anim
advoc
elicit
strong
cellular
respons
essenti
combat
intracellular
pathogen
shigella
surg
infc
level
ensur
inhibit
cytosol
replic
shigella
therebi
reduc
suscept
shigella
infect
vaccin
anim
moreov
proinflammatori
cytokin
infc
also
report
antiinflammatori
activ
along
interplay
cytokin
antiinflammatori
properti
infc
well
also
observ
present
studi
wherein
colon
length
vaccin
anim
reduc
even
follow
shigella
infect
strengthen
protect
role
infc
shigella
infect
observ
protect
induct
follow
vaccin
studi
line
role
prevent
bacteri
induc
inflamm
follow
vaccin
establish
research
collect
observ
protect
lacvax
ompa
immun
anim
attribut
presenc
antigen
specif
igg
siga
higher
level
infc
preinfect
time
point
observ
accord
exist
literatur
antigen
specif
igg
siga
antibodi
higher
level
infc
strongli
correl
protect
shigella
infect
follow
vaccin
strengthen
vaccin
candid
lacvax
ompa
howev
detail
immunolog
studi
warrant
understand
underli
mechan
protect
would
strengthen
candidatur
lacvax
ompa
colon
length
reduct
disrupt
tissu
integr
key
indic
sever
inflamm
follow
shigella
infect
intact
intestin
tissu
adequ
colon
length
vaccin
anim
follow
shigella
infect
demonstr
protect
immun
respons
vaccin
candid
potenti
l
lacti
base
antigen
deliveri
platform
gener
protect
immun
respons
establish
even
variou
infect
listeria
monocytogen
escherichia
coli
pneumococc
serotyp
rotaviru
human
papillomaviru
severaloth
diseas
develop
vaccin
candid
sever
benefit
low
product
cost
safe
profil
needlefre
administr
conveni
mass
immun
furthermor
immunostimulatori
adjuv
properti
l
lacti
help
counteract
vaccin
loss
make
lower
immunogen
nonliv
vaccin
consid
patient
complianc
unsaf
usag
needl
cost
rapid
increas
incid
crosscontamin
use
l
lacti
base
vaccin
platform
well
suit
model
needlefre
oral
mucos
vaccin
enter
pathogen
moreov
platform
also
use
develop
protect
prophylact
enter
pathogen
author
concur
submiss
